1
Country: South Korea | Funding: ₩27B
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
Aston Sci develops cancer vaccines based on mRNA, DNA and peptides, which are currently being evaluated for efficacy in breast and gastric cancer. The company has created a cloud-based Collaborative Drug Discovery platform, powered by the Th-Vac AI epitope screening system and supported by an antigen-based epitope prediction program. Using the platform's results, the company performs precise immunological screening, enabling the identification of highly selective epitopes specific to MHC class II, known for their ability to induce strong and sustained CD4⁺ T-cell immunity. By integrating multi-omics datasets with machine learning, Th-Vac overcomes key barriers in the development of off-the-shelf vaccines encoding TAAs (tumor-associated antigens) or TCAs (tumor-specific antigens), as well as personalized neoantigen vaccines, including tumor heterogeneity, lengthy manufacturing lead times, and limited patient applicability.
2
Country: Norway | Funding: $13.1M
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
Zelluna Immunotherapy is developing a unique and proprietary TCR-NK cell therapy platform for the treatment of cancer. The therapy utilizes human (donor) natural killer (NK) cells, driven by T-cell receptors (TCRs), which are administered to patients. TCRs provide precise targeting of cancer cells and enable NK cells to find and destroy cancer cells within the patient's body. Zelluna's development pipeline targets a combination of clinically or preclinically validated antigens expressed in a broad range of solid tumors, providing high potential for patient impact and a significant market opportunity. The company's undergoing clinical trials include the following indications: NSCLC, ovarian cancer, sarcoma, breast cancer, gastric cancer, lung cancer, pancreatic cancer, cervical cancer.
3
Country: Italy | Funding: $220M
MMI (Medical Microinstruments) produces the world's most precise surgical robot, Symani with smallest wristed instruments. It allows surgeons to operate on lymphatic vessels smaller than 0.5 millimeters, while the physician monitors the procedure on a screen with a raised outline. The system is designed to perform microsurgical anastomoses, suture and ligate blood vessels, lymphatic ducts, and nerves, as well as for soft tissue dissection during open surgery. Symani is successfully used in neurosurgery, breast reconstruction after cancer, and lymphatic drainage procedures. MMI has also received FDA approval for clinical trials of surgical treatment for Alzheimer's disease.
MMI (Medical Microinstruments) produces the world's most precise surgical robot, Symani with smallest wristed instruments. It allows surgeons to operate on lymphatic vessels smaller than 0.5 millimeters, while the physician monitors the procedure on a screen with a raised outline. The system is designed to perform microsurgical anastomoses, suture and ligate blood vessels, lymphatic ducts, and nerves, as well as for soft tissue dissection during open surgery. Symani is successfully used in neurosurgery, breast reconstruction after cancer, and lymphatic drainage procedures. MMI has also received FDA approval for clinical trials of surgical treatment for Alzheimer's disease.
4
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
5
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
6
Country: UK | Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
7
Country: USA | Funding: $280.8M
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
8
Country: USA | Funding: $220M
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
Paige.AI was one of the first startups to apply AI models to cancer care and has since developed numerous models used for tissue analysis, tissue subtyping and molecular biomarker discovery. Paige has developed several AI applications for diagnostic decision support in oncology pathology, including prostate cancer detection and diagnosis in whole-section prostate biopsy images, identifying and classifying breast cancer in whole-section biopsy and excisional breast specimens, detecting and classifying benign and malignant diseases throughout the gastrointestinal tract. Developed using Virchow and trained on over 1.5 million slides, the Paige PanCancer Suite helps pathologists identify the subtlest nuances of cancer progression in various tissue types, including rare cancers. Acquired by Tempus
9
Country: USA | Funding: $208.3M
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
Halda is developing RIPTAC - a new class of precision anti-cancer drugs. RIPTAC technology binds two proteins: one specific to the tumor and one that performs an essential function. This protein-protein interaction enables to selective destruct cancer cells. Halda's portfolio includes oral therapeutic drugs for treatment of metastatic castration-resistant prostate cancer and breast cancer. Clinical trials have already demonstrated good tolerability of this new therapy and encouraging signs of anti-tumor activity, including reductions in prostate-specific antigen (PSA) levels and Response Evaluation Criteria in Solid Tumors (RECIST) responses in patients with advanced prostate cancer, many of whom have progressed after several prior therapies and exhausted available treatment options. Acquired by Johnson & Johnson
10
Country: Singapore | Funding: $187M
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
11
Country: Canada | Funding: $120.1M
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
Oncolytics Biotech is developing REOLYSIN®, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that targets cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological malignancies.
12
Country: USA | Funding: $112.3M
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
Insight Molecular Diagnostics (iMDx) develops and provides diagnostic tests for oncology. The company is developing three genetic tests: blood tests for breast and lung cancer and a urine test for bladder cancer. iMDx has also developed a blood-based transplant monitoring test that quantifies the concentration of donor cell-free DNA (dd-cfDNA) after transplantation. The company partners with biotech research laboratories and supplies them with tests intended exclusively for research purposes in oncology and transplantation research projects.
13
Country: USA | Funding: $106M
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
Totus Medicines develops precision oral therapeutics for cancer treatment. The company uses own drug discovery platform OmniDEL, which utilizes artificial intelligence/machine learning and innovative DNA-encoded covalent library technology to search for small molecule drugs. The startup conducts ultra-high-throughput cell-based screening of these molecules using its proprietary labeling technology for cellular analysis. The company's flagship drug, TOS-358, is a precision oral drug for the treatment of cancers with PI3Kα mutations (the most frequently mutated oncogene in a wide range of cancers, for which there are currently no drugs that provide potent, specific and long-lasting inhibition without significant toxicity). TOS-358 is currently in clinical trials for the treatment of hormone receptor-positive breast, endometrial and head and neck cancers expressing PI3K-alpha mutations.
14
Country: Israel | Funding: $72M
Ayala Pharmaceuticals develops a personalized treatment for cancer.
Ayala Pharmaceuticals develops a personalized treatment for cancer.
15
Country: Switzerland | Funding: $65.7M
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
16
Country: UK | Funding: $52M
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
17
Country: UK | Funding: $39.8M
Around the world the incidence of cancer is growing, and with it the demand for better, faster and less expensive solutions for diagnosis and treatment. With the aim of bringing cancer care to everyone, everywhere, Endomag is developing a clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices, avoiding the safety, workflow and availability concerns of ionizing radiation.
Around the world the incidence of cancer is growing, and with it the demand for better, faster and less expensive solutions for diagnosis and treatment. With the aim of bringing cancer care to everyone, everywhere, Endomag is developing a clinical platform that uses safe magnetic fields to power diagnostic and therapeutic devices, avoiding the safety, workflow and availability concerns of ionizing radiation.
18
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
19
Country: UK | Funding: $22m
Kheiron Medical Technologies aims to help radiologists detect breast cancer earlier by using deep learning
Kheiron Medical Technologies aims to help radiologists detect breast cancer earlier by using deep learning
20
Country: USA | Funding: $18.8M
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
4D Path develops QPOR platform, designed to directly measure and quantify cell cycle abnormalities and tumor microenvironment dynamics to predict patient response to therapy. It uses hematoxylin and eosin (H&E)-stained biopsy images to instantly uncover hidden data, enabling biomarker profiling and stratification. While the company initially focuses on breast cancer, it is actively developing products for ovarian cancer, cervical cytology, skin cancer, and, more broadly, immunotherapy for various cancer types.
21
Country: Australia | Funding: $17.1M
OncoRes Medical develops an imaging technology to provide intraoperative information available to breast cancer surgeons.
OncoRes Medical develops an imaging technology to provide intraoperative information available to breast cancer surgeons.
22
Country: Russia
BioCAD is a full-cycle drug development and manufacturing company with a world-class research and development center.
BioCAD is a full-cycle drug development and manufacturing company with a world-class research and development center.
23
Country: France | Funding: $7.2M
Primaa develops software tools which use artificial intelligence (AI) and deep learning to assist anatomical pathologists with cancer (in particular breast cancer) and other diagnoses.
Primaa develops software tools which use artificial intelligence (AI) and deep learning to assist anatomical pathologists with cancer (in particular breast cancer) and other diagnoses.
24
Country: India | Funding: $7M
Niramai uses machine learning and AI to fight against the inaccessibility of breast examinations. They use a low-cost, portable device that takes high-res thermal images, or an alternative to traditional mammography exams and may be better with early indicators, too.
Niramai uses machine learning and AI to fight against the inaccessibility of breast examinations. They use a low-cost, portable device that takes high-res thermal images, or an alternative to traditional mammography exams and may be better with early indicators, too.
25
Country: India | Funding: $6.4M
UE LifeSciences created a breast exam device that uses cold air and heat sensors to check for vascular responses, metabolic activity, and thermal symmetry between breasts. Called the NoTouch BreastScan, this works different from a mammography that tests for physical concerns like tumors.
UE LifeSciences created a breast exam device that uses cold air and heat sensors to check for vascular responses, metabolic activity, and thermal symmetry between breasts. Called the NoTouch BreastScan, this works different from a mammography that tests for physical concerns like tumors.
26
Country: USA | Funding: $5.9M
Cyrcadia Health, creator of the iTbra, offers a discreet insert that goes under any bra, and empowers women to enhance their monthly breast self-exam in their own home. Their patches detect circadian temperature changes within breast tissue, and uses machine-learning algorithms to collect data and communicate it to Cyrcadia Health.
Cyrcadia Health, creator of the iTbra, offers a discreet insert that goes under any bra, and empowers women to enhance their monthly breast self-exam in their own home. Their patches detect circadian temperature changes within breast tissue, and uses machine-learning algorithms to collect data and communicate it to Cyrcadia Health.
27
Country: USA | Funding: $5.4M
iSono Health develops a wearable solution to monitor breast health.
iSono Health develops a wearable solution to monitor breast health.
28
Country: USA
CureMetrix offers a next generation of medical image analysis for Mammography.
CureMetrix offers a next generation of medical image analysis for Mammography.
29
Country: Singapore | Funding: $4.1M
FathomX is a Medical Imaging AI Spin-Off for breast cancer analysis from the National University of Singapore
FathomX is a Medical Imaging AI Spin-Off for breast cancer analysis from the National University of Singapore
30
Country: USA | Funding: $3.7M
TeVido BioDevices uses the innovative process of 3D bio-printing of living human cells for use as implants or grafts targeting use in reconstructive surgery and wound care. TeVido will change the way reconstructive surgery is approached, starting by improving options for breast cancer survivors but expanding capability to others who suffer disfigurement and long to improve their self-esteem.
TeVido BioDevices uses the innovative process of 3D bio-printing of living human cells for use as implants or grafts targeting use in reconstructive surgery and wound care. TeVido will change the way reconstructive surgery is approached, starting by improving options for breast cancer survivors but expanding capability to others who suffer disfigurement and long to improve their self-esteem.
31
Country: UAE | Funding: $100K
Prognica is building smart screening solution for early detection of breast cancer using artificial intelligence and machine learning.
Prognica is building smart screening solution for early detection of breast cancer using artificial intelligence and machine learning.
32
Country: Sweden
Thermaiscan is combining AI with thermal sensors in smartphones to solve the problem with late detection of breast cancer development. The innovation is enhancing non-specialist healthcare personnel with a breast cancer pre-screening solution. It is for the first line of healthcare that has the very first contact with patients in mini clinics, primary care units and in rural areas.
Thermaiscan is combining AI with thermal sensors in smartphones to solve the problem with late detection of breast cancer development. The innovation is enhancing non-specialist healthcare personnel with a breast cancer pre-screening solution. It is for the first line of healthcare that has the very first contact with patients in mini clinics, primary care units and in rural areas.
33
Country: USA
Whiterabbit has developed a line of products targeting the mammography space to enable early and accurate breast cancer detection.
Whiterabbit has developed a line of products targeting the mammography space to enable early and accurate breast cancer detection.
34
Country: Canada
AI Talos provides AI-guided decision-making support for breast cancer screening (Thermography), enabling you to decisively confirm what you suspect, detect what you potentially missed and concentrate on questionable studies that need more attention.
AI Talos provides AI-guided decision-making support for breast cancer screening (Thermography), enabling you to decisively confirm what you suspect, detect what you potentially missed and concentrate on questionable studies that need more attention.
